Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine

NCT05216263 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05216263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
March 22, 2022
Completion date
May 2, 2025
Enrollment
75 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine